Table 2.

Demographics and Medications Taken by Participants in First Trial Arm.

Demographics	Participants Receiving Yoga First	Participants Receiving Psychoeducation First	All Participants
Mean age (SD)	39.36 (11.69)	40.58 (12.72)	39.68 (11.89)
Gender N (%)
Female	43 (81.10)	14 (73.70)	57 (79.20)
Male	10 (18.90)	5 (26.30)	15 (20.80)
Mood diagnosis N (%)
Unipolar	44 (83.0)	11 (57.90)	55 (76.40)
Bipolar	9 (17.0)	8 (42.10)	17 (23.60)
Mean baseline MADRS score (SD)	19.18 (5.91)	18.42 (5.66)	18.97 (5.81)
Mean duration of illness years (SD)	9.82 (9.12)	12.05 (9.80)	10.41 (9.29)
Comorbid diagnosis N (%)	26 (49.1)	10 (52.60)	36 (50.0)
Family history of psychiatric disorder N (%)	47 (88.70)	13 (68.40)	60 (83.30)
Receiving psychotropic medication N (%)	52 (98.1)	18 (94.70)	70 (97.20)
Marital status N (%)
Married	6 (11.30)	3 (15.80)	9 (12.50)
Single	16 (30.20)	7 (36.80)	23 (31.90)
In long-term relationship	10 (18.90)	4 (21.10)	14 (19.40)
Divorced	10 (18.90)	2 (10.50)	12 (16.70)
Widowed	2 (3.80)	1 (5.30)	3 (4.20)
Employment status N (%)
Full-time	5 (9.40)	2 (10.50)	7 (9.70)
Part-time	13 (24.50)	1 (5.30)	14 (19.40)
Not currently working	29 (54.70)	13 (68.40)	42 (58.30)
Student	2 (3.80)	1 (5.30)	3 (4.20)
Education level N (%)
High school	4 (7.60)	2 (10.50)	6 (8.30)
College	6 (11.30)	6 (31.60)	12 (16.70)
University	37 (69.80)	7 (36.80)	44 (61.10)
Graduate studies	5 (9.40)	4 (21.10)	9 (12.50)
Medication type N (%)
SSRI	23 (48.9)	7 (38.9)	30 (46.2)
SNRI	23 (48.9)	7 (38.9)	30 (46.2)
Tricyclic	2 (4.3)	2 (11.1)	4 (6.2)
Atypical antipsyhcotic	11 (23.4)	8 (44.4)	19 (29.2)
Mood stabilizer	9 (19.1)	6 (33.3)	15 (23.1)
Benzodiazepine	13 (27.7)	4 (22.2)	17 (26.2)
Other (stimulant, sleep aid)	6 (12.8)	4 (22.2)	10 (15.4)

Note. N = 72.